Skip to content

Capreomycin

    Brands

    DEA Class; Rx

    Common Brand Names; Capastat

    • Antitubercular Agents

    Parenteral polypeptide antibiotic, exact mechanism unknown.
    Used as a second line agent in combination with other medications for the treatment of pulmonary tuberculosis.
    Practical use is limited by routes of administration, adverse effects of nephrotoxicity and neurotoxicity.

    Indicated for treatment of Tuberculosis

    Hypersensitivity

    Pregnancy

    • Nephrotoxicity, incr BUN (36%)
    • Hearing loss (11% subclinical; 3% clinical)
    • Eosinophilia (dose related, >5%)
    • Incr LFTs
    • Inj site pain/induration
    • Leukopenia
    • Maculopapular rash
    • Urticaria

    Renal impairment, auditory impairment, history of allergic rxns

    Risk of hypokalemia

    Risk of rare but potentially fatal toxic nephritis

    Pregnancy Category: C

    Lactation: excretion in milk unknown; use with caution

    Adults

    1 g/day (20 mg/kg/day) or 5 days/week IV/IM or 25 mg/kg/dose IV/IM 3 days/week.

    Geriatric

    1 g/day (20 mg/kg/day) or 5 days/week IV/IM or 25 mg/kg/dose IV/IM 3 days/week.

    Adolescents

    Safety and efficacy have not been established; however, 30 mg/kg/day (Max: 1 g/day), 5 days/week, or twice weekly IV/IM has been used off-label.

    Children

    Safety and efficacy have not been established; however, 30 mg/kg/day (Max: 1 g/day), 5 days/week, or twice weekly IV/IM has been used off-label.

    Infants

    Safety and efficacy have not been established; however, 30 mg/kg/day, 5 days/week, or twice weekly IV/IM has been used off-label.

    Neonates

    Safety and efficacy have not been established; however, 30 mg/kg/day IV/IM has been used off-label.

    Capreomycin sulfate

    powder for injection

    • 1g/vial